Trial Profile
A study to evaluate the efficacy of mirabegron in patients with nocturia predominant hypersensitive bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2016
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Nocturia; Overactive bladder
- Focus Therapeutic Use
- 24 Oct 2016 New trial record
- 16 Sep 2016 Efficacy results (n=260) presented at the 46th Annual Meeting of the International Continence Society.